Literature DB >> 3128951

Continuous terbutaline nebulization for the treatment of severe exacerbations of asthma in children.

J Portnoy1, J Aggarwal.   

Abstract

Twelve children with severe asthma were treated in an intensive care unit with continuously nebulized terbutaline at doses between 1.0 and 12.0 mg/hour. All patients showed improvement in blood gases, pulse, and respiratory rates. None experience significant side effects. The duration of therapy ranged from 1 to 24 hours (mean = 8.3 hours), and all were able to leave the intensive care unit within one day. The use of continuously nebulized terbutaline appears to be safe and effective for the treatment of severe asthma in children in this limited experience.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128951

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  4 in total

Review 1.  Pharmacologic management of the hospitalized pediatric asthma patient.

Authors:  K A Hardin; H J Kallas; R J McDonald
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

Review 2.  Asthma: a follow up statement from an international paediatric asthma consensus group.

Authors: 
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

3.  Continuous nebulised salbutamol and oral once a day prednisolone in status asthmaticus.

Authors:  M Singh; L Kumar
Journal:  Arch Dis Child       Date:  1993-10       Impact factor: 3.791

4.  Progress in the management of childhood asthma.

Authors:  Pakit Vichyanond; Rattana Pensrichon; Suruthai Kurasirikul
Journal:  Asia Pac Allergy       Date:  2012-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.